To examine the effect of the GSNOR inhibitor, SPL-334, on allergic airway inflammation and whether the inhibitor limited the inflammation mediated by fully differentiated CD4+ Th2 cells, we used the passive transfer of Th2 cell model of asthma. Here, CD4 is linked to asthma.